Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion

NCT ID: NCT01042964

Last Updated: 2012-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2007-10-31

Brief Summary

Primary objective:

To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests

Secondary objectives:

To evaluate the pharmacokinetics and pharmacodynamics (platelet aggregation)of six ascending single intravenous doses of PR-15 in healthy volunteers

Detailed Description

Primary objective:

To evaluate safety and tolerability by using adverse events (AEs), vital signs including blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG), bleeding time, evaluation of antibody titer and safety laboratory tests (biochemistry, hematology, coagulation, urinalysis)

Secondary objectives:

To evaluate the pharmacokinetics and pharmacodynamics (collagen-induced platelet aggregation)of six ascending single intravenous doses of PR-15 in healthy, male volunteers

Conditions

Thrombosis; Acute Coronary Syndrome; Myocardial Infarction; Stroke

Keywords

platelet adhesion and aggregation; acute coronary syndrome; myocardial infarction; stroke; inhibition of platelet adhesion to plaques; collagen-induced platelet aggregation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

revacept (PR-15)

single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.

Intervention Type: DRUG

Other Intervention Names

GPVI-Fc dimer

Eligibility Criteria

Inclusion Criteria

• Healthy, male Caucasians between 18 and 45 years of age.
• Normotensive subjects (systolic BP < 140 mmHg and diastolic BP <90 mmHg;
• Body weight of 70 to 90 kg (BMI 20 - 25.
• Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests;
• Signed Informed Consent Form.
• Normal coagulation function (aPTT between 24 and 35 seconds, PT between 70 and 130%, INR between 0.85 and 1.15.

Exclusion Criteria

• Subjects who are taking or have taken any prescription medication within the last 14 days or any non-prescription medication, especially, anti-platelet drugs, within the last seven days prior to the administration of trial medication on Day 1.
• Intake of any investigational drug within three months prior to the administration of study medication on Day 1.
• Concomitant use of any other medication including over-the-counter preparations.
• History of hypersensitivity, contraindication or serious adverse reaction to inhibitors of platelet aggregation or hypersensitivity to related drugs (cross-allergy) or to any of the excipients in the study drug.
• A history or clinical evidence of any cardiac, cardio- or cerebrovascular, hepatic, renal, pulmonary, endocrine, neurological, infectious, gastrointestinal, haematological, oncological or psychiatric disease or emotional problems or any other clinically relevant condition, physical finding, ECG- or laboratory test abnormality, which - in the opinion of the investigator - would pose a significant risk for the subject, invalidate the Informed Consent or limit the ability of the subject to comply with study requirements or interfere otherwise with the conduct of the study.
• Any laboratory value outside the normal laboratory reference range at Screening and before randomization, unless approved by the investigator.
• Subjects known to have experienced elevated liver enzyme values will also be excluded.
• History of alcohol and/or drug abuse (verified by drug screening).
• Blood loss of 450 ml or more during the last three months before Screening.
• Subjects who smoke more than 5 cigarettes per day and/or are unable to abstain from smoking during the entire in-house period.
• Subjects who were previously enrolled in this trial or who have received PR-15 in a previous trial.
• Subjects who have participated in other clinical trials in the last 3 months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Procorde GmbH

UNKNOWN

Sponsor Role: collaborator

AdvanceCor GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Piechatzek, MD

Role: PRINCIPAL_INVESTIGATOR

ABX-CRO/Medifacts GmbH

Locations

ABX-CRO/Medifacts GmbH

Görlitz, Saxony, Germany

Countries

Germany

References

Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Munch G. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011 May 3;123(17):1891-9. doi: 10.1161/CIRCULATIONAHA.110.980623. Epub 2011 Apr 18.

Reference Type: RESULT

PMID: 21502572 (View on PubMed)

Other Identifiers

EudraCT 2005-004656-12

Identifier Type: REGISTRY

Identifier Source: secondary_id

PR-15/01

Identifier Type: -

Identifier Source: org_study_id